B+
Bull case
25%
Probability
Target price
$11.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
SLN
Silence TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is that divesiran is the primary asset the market cares about and the company has already de-risked execution somewhat by finishing SANRECO enrollment ahead of schedule, with 3Q 2026 topline data now the key unlock [#PR-2025-10-23][#PR-2026-03-05].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
AstraZeneca notified Silence on March 4, 2026 that it will not pursue further SLN312 development beyond Phase 1, reducing one external validation path.
Momentum
96
Value
41
Sentiment
2
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $6.50 · Bull $11.00 · Bear $3.50Analysis 2026-04-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $35.80
Why
Momentum96 · Δ7d -1.0
Value41 · Δ7d -0.0
Sentiment2 · Δ7d +1.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • AstraZeneca notified Silence on March 4, 2026 that it will not pursue further SLN312 development beyond Phase 1, reducing one external validation path.
- • Collaboration revenue dropped materially in 2025, increasing dependence on internal execution and future partnering.
- • The bear case is that SLN remains a narrow, single-major-readout story after collaboration revenue fell sharply in 2025 and the 10-K disclosed AstraZeneca will not pursue further SLN312 development beyond Phase 1, reducing partnership optionality [#PR-2026-03-05][#10-K-2026-03-05].
Catalyst clock
2026-06-30
Second-quarter 2026 preclinical updates on SLN365 and SLN098
Lead driver: Value · See fundamentals
Momentum
96
9% active weight
Current posture
7d trendSoftening
Δ7d
-1.0
Δ21d
-2.3
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
2
62% active weight
Current posture
7d trendImproving
Δ7d
+1.4
Δ21d
+1.4
Why this grade
Composite grade F. Momentum 96.5 / Value 41.2 / Sentiment 2.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-15. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$3.50
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$677.99M
Beta
0.56
Shares Out
47.25M
P/E (TTM) · Derived
-7.6
P/S (TTM)
10.85
P/FCF (TTM)
6.91
Rev YoY
-100.0%
EPS YoY
-55.6%
Gross Margin
+15.8%
Op Margin
-8531.4%
Net Debt
-$84.95M
Current Ratio
7.42
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data